BAX stock: buy or sell?
August 22nd, 2019
Baxter International Inc. provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments.
Should I buy BAX stock?Even if you are a experienced or a novel trader, best trading results come from using an investing strategy that never leaves to random or subjective opinions when is the best moment to buy or sell stocks. That's why is so important to define your own trading strategy that fits your character as inversor. At Stocks2.com, we like to use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.
Currently, 2 buy setups work for Baxter International stock now:
|New all-time high||Yes|
|New 52 week high||Yes|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Baxter International stock a buy?
Banks and financial institutions publish stock ratings everyday.At Stocks2.com, we collected 14 ratings published for BAX stock in the last 30 days. The general sentiment of these ratings is bullish for BAX stock, with 12 positive ratings.
|Date||Analyst / Broker||Previous rating||Current rating|
|2019-7-26||Credit Suisse Group||Reduce||Outperform|
|2019-7-26||Credit Suisse Group||Reduce||Outperform|
|2019-7-26||BMO Capital Markets||n/a||Outperform|
|2019-6-26||Wells Fargo & Co||n/a||Outperform|
|2019-6-20||Piper Jaffray Companies||n/a||Overweight|
|2019-5-13||JPMorgan Chase & Co.||n/a||Overweight|
|2019-4-3||Wells Fargo & Co||n/a||Outperform|
|2019-4-15||Barclays||Equal Weight||Equal Weight|
|2019-2-1||Piper Jaffray Companies||n/a||Overweight|
|2019-1-2||Morgan Stanley||Equal Weight||Overweight|
BAX stock analysis
After several days of continuous hikes in past weeks, Baxter International remained stable -0.11% to $87.21.
Baxter International remained constant -0.11% to $87.21 after topping to all time highs on Aug 20th. On April, SMA100d and SMA200d crossed up triggering a rise of 9.86%. Since price and SMA100d lines crossed up on June, BAX climbed $13.46 (18.25%). On Aug 20th, BAX hit a new all time high, pushing higher than on Aug/13 tops. Check different trading setups that use ATHs as triggers.
Baxter International stayed stable 0.28% this week and reached a new all time high at $88.48. Counting this, it's been 3 climbing weeks in a row, soaring a 2.95%.
BAX shows a strong mid-term uptrend with several rising tops and rising bottoms. Since its last bottom early August, BAX climbed unceasignly breaking out to new all time highs. Since SMA20d and SMA40w crossed up early April, BAX price climbed $6.77 per share (8.42%). Late January BAX price bounced up over the SMA of 40 weeks that acted as support stopping new slides.
BAX stock price history
BAX stock went public on October 27th, 1981 with a price of $0.421. Since then, BAX stock surged a 20,664.30%, with an average of 558.50% per year. If you had invested $1,000 in BAX stock in 1981, it would worth $206,643.00 today.
1: Adjusted price after possible price splits or reverse-splits.
BAX stock historical price chart
BAX stock reached all-time highs on August 20th with a price of $88.48.
BAX stock price target is $85.80Nobody can reliably foresee how stock prices may evolve in the future. However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. The accuracy of these stock price predictions is not very high, and you should not blindly believe and make decisions only based on what this ratings or price target predictions say. For the last month we found 14 price targets for BAX stock:
|Date||Analyst / Broker||Action||Previous target||Current target||Diff|
|2019-7-26||Raymond James||Raises Target||$84.00||$95.00||13.1%|
|2019-7-26||Credit Suisse Group||Reiterates||$84.00||$95.00||13.1%|
|2019-7-26||Credit Suisse Group||Raises Target||$84.00||$95.00||13.1%|
|2019-7-26||BMO Capital Markets||Raises Target||n/a||$95.00||-|
|2019-6-26||Wells Fargo & Co||Raises Target||$89.00||$91.00||2.2%|
|2019-6-20||Piper Jaffray Companies||Reiterates||$80.00||$90.00||12.5%|
|2019-5-13||JPMorgan Chase & Co.||Reiterates||$80.00||$88.00||10%|
|2019-4-3||Wells Fargo & Co||Reiterates||$80.00||$89.00||11.3%|
|2019-3-5||Morgan Stanley||Raises Target||$80.00||$83.00||3.8%|
|2019-2-1||Piper Jaffray Companies||Reiterates||n/a||$80.00||-|
Financials and fundamental analysis
Earnings date and Earnings per ShareAfter posting its last earnings report on April, Baxter International boosted a brilliant 14.57%. As soon as we get its actual EPS from the earnings report, we will extend this report.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsIn 2018, Baxter International annual revenues escalated a beatiful 5.36% to $11,127.00 million USD from $10,561.00 marked in 2017. On the other hand, its earnings margin (compared to revenues) jumped to 14.60%, that is $1,624.00 million. Baxter International fiscal year ends in December, and to compare its evolution since then, we estimate annual sales and income figures by adding results from the last 4 quarters. This is called TTM (or Twelve Trailing Months). So, Baxter International TTM sales up to March 2019 were $11,082.00 and income $1,582.00 million USD. If we compare this TTM figures with the last reported annuality, we can review Baxter International business evolution since December 2018: Annual revenues up to March, compared to lastest yearly report, stayed stable a tight -0.40%. Regarding profit margin, Baxter International remained constant -0.32% to 14.60%
|2013||$15,260 M||-||$2,010 M13.2%||-|
|2014||$16,671 M||9.25%||$2,497 M15.0%||24.23%|
|2015||$9,968 M||-40.21%||$968 M9.7%||-61.23%|
|2016||$10,163 M||1.96%||$4,965 M48.9%||412.91%|
|2017||$10,561 M||3.92%||$717 M6.8%||-85.56%|
|2018||$11,127 M||5.36%||$1,624 M14.6%||126.50%|
|TTM||$11,082 M||-0.40%||$1,582 M14.3%||-2.59%|
Quarterly financial resultsBaxter International posted $2,632.00 million in sales for 2019-Q1, a -7.36% decline compared to previous quarter. Reported quarter earnings marked $347.00 M with a profit margin of 13.18%. Profit margin stayed steady a 0.93% compared to previous quarter when profit margin was 12.25%. When comparing revenues to same quarter last year, Baxter International sales marked a lame drop down and slightly fell a -1.68%.
|2017-Q2||$2,610 M||-||$264 M10.1%||-|
|2017-Q3||$2,710 M||3.83%||$248 M9.2%||-6.06%|
|2017-Q4||$2,774 M||2.36%||$-71 M-2.6%||-128.63%|
|2018-Q1||$2,677 M||-3.50%||$389 M14.5%||-647.89%|
|2018-Q2||$2,842 M||6.16%||$343 M12.1%||-11.83%|
|2018-Q3||$2,767 M||-2.64%||$544 M19.7%||58.60%|
|2018-Q4||$2,841 M||2.67%||$348 M12.2%||-36.03%|
|2019-Q1||$2,632 M||-7.36%||$347 M13.2%||-0.29%|
Baxter International ownershipWhen you are planning to invest in shares of a stock, it's always worth to overview its ownership structure.
Baxter International shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 0.13% of all shares.
Bearish positions for BAX stock account 0.00%, no big difference from last month.
For a better understanding, the following table shows ownership data compared to other related companies:
|Market cap||$44.5 B||$68.8 B||$59.3 B||$13.0 B||$2.4 B|
|Total shares||510.2 M||269.7 M||1,390.0 M||298.1 M||145.5 M|
|Float shares||509.5 M||269.1 M||1,390.0 M||296.8 M||134.0 M|
|- Institutional holdings (%)||88.2%||87.5%||93.4%||92.4%||0.0%|
|- Insider holdings (%)||0.1%||0.3%||0.2%||0.3%||8.5%|
|Shares in short selling||0.0%||0.0%||0.0%||0.0%||0.0%|
|Thursday, August 22nd, 2019|
|Day range||$86.64 - $87.79|
|Average true range||$1.82|
|50d mov avg||$83.35|
|100d mov avg||$79.98|
|200d mov avg||$74.79|
Baxter International performanceTo better understand Baxter International performance you must becnhmark its gains with other related stocks in same sector or industry. We compared Baxter International against Becton, Dickinson and, Boston Scientific, Cardinal Health, Halozyme Therapeutics, ICU Medical, Medtronic, Owens & Minor, Stryker, Thermo Fisher Scientific and Zimmer Biomet in the following table:
|OMIOwens & Minor||35.06%||-26.22%||-71.01%|
|TMOThermo Fisher Sci...||2.45%||10.53%||18.89%|